Atrial Fibrillation Revisited —With a Special Reference to Primary Prevention—  by Aizawa, Yoshifusa et al.
Atrial Fibrillation Revisited
—With a Special Reference to Primary Prevention—
Yoshifusa Aizawa MD, Hiroshi Furushima MD, Hiroshi Watanabe MD
Division of Cardiology, Hemotology and Endocrinology, Niigata University Graduate School of
Medical and Dental Science, Niigata, Japan
(J Arrhythmia 2007; 23: 4–11)
Atrial ﬁbrillation (AF) is common arrhythmia and
results in a rapid and irregular rhythm. Patients with
this arrhythmia may be asymptomatic but AF often
causes palpitation or chest discomfort especially
when it develops in its paroxysmal form and patients
might develop fatigue easily or reduced working
capacity. Because of a loss of atrial contribution to
ventricular ﬁlling, AF results in a decrease of cardiac
output by 15% at rest and up to 30% upon exercise.1)
Long-standing tachycardia leads to cardiac dysfunc-
tion known as tachycardia-induced cardiomyopathy2)
and AF can be the cause of such cardiomyopahty and
results in atrial stunning.3)
The prevalence of AF increases with advanced
age: 0.4% in the general population but less than
6% in those >80 years4,5) and the elder patients are
prone to develop heart failure. Rarely, AF can be
fatal in WPW syndrome when rapid ventricular
activation occurs via the Kent bundle.6)
In addition to such morbidity, AF is the major
cause of stroke and is associated with increased
mortality and morbidity.7–9) For stroke in patients
with AF, several risk factors have been establish-
ed8–13) and in animal model, altered gene expression
predisposing to coagulation was conﬁrmed in the
endocardium of the paced-atrium.14) To reduce
stroke, eﬃcacy of anticoagulant therapy by Warfarin
is well established.12,13) Aspirin seems to be ineﬃca-
cious especially in Japan to prevent stroke due to
AF.15)
For AF, antiarrhythmic drugs are prescribed to
prevent recurrence but with limited eﬃcacy. The
best result in preventing the recurrence of AF is that
reported by CTAF using amiodarone, wherein the
AF free rate was 60% at the 600th day of therapy.16)
However, the drug might be withdrawn because of
side eﬀects and paroxysmal AF progresses even-
tually to chronic AF over time.17)
Recently, catheter ablation has been established as
a new promising therapy to prevent the recurrence of
AF18) but it would be diﬃcult to apply catheter
ablation to every patient because of the large number
of patients. For these reasons, we have to seek other
possibilities and the prevention of the occurrence of
AF in the general population is very important. We
hereby, review the epidemiology and the underlying
diseases of AF from the point of view of primary
prevention of AF.
Associated Disorders and Genesis of AF
Though AF can occur in subjects without disease
and with normal cardiac function,19) it occurs more
often in association with familiar diseases.
The prevalence of AF associated with well-known
cardiac or non-cardiac diseases is shown in Table 1
which was presented in the guideline of AF treat-
ment in this country.20) The prevalence of each
disorder was determined in the institutions of the
committee members.
A more precise prevalence of AF was determined
in 19,825 patients who visited cardiovascular clinics
of 13 hospitals in Hokkaido, Japan.21) AF, was found
in 14% and increased with age: for the age groups of
<40, 40–50, 50–60, 60–70, 70–80 and >80 were
3.5%, 6.9%, 10.4%, 13.5%, 18.7% and 25.4%,
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respectively. The underlying heart diseases of AF
were hypertension (29%), valvular heart disease
(19%), ischemic heart disease (11%), cardiomyop-
athy (5%), sick sinus syndrome (1%), WPW syn-
drome (5%) and others (33%). The prevalence of AF
in these two reports was higher than that determined
in the general population.
The main factor causing AF in these diseases is
considered to be stretching of the left atrium22,23)
as found in heart failure, hypertension, myocardial
infarction and cardiomyopathy and the prevalence
and the incidence of AF increases as the cardiac
function worsens: the prevalence of AF can be found
in 10–15%, 26%, and up to 50% for NYHAI–II, III–
IV and IV, respectively.24)
When the atrium undergoes stretching, the renin-
agniotensin system (RAS) is considered to be ac-
tivated in the atrium and plays a major role in
inducing structural remodeling or expression of
oxidative stress.26–29) This activation has been con-
ﬁrmed in the atrium with AF26) and in the rapidly
paced atrium.27,28) In spontaneously hypertensive
rats (SHR), oxidative stress expression and ﬁbrosis
was detected. This ﬁnding suggests that both ﬁbrosis
and oxidative stress occur prior to the onset of AF
and they were found to be attenuated by hypotensive
therapy: most eﬀectively by angiotensin II type-1
receptor blockade.30)
Altered autonomic nerve activities is another
precipitating factor of AF31,32) and some patients
develop AF exclusively at night or show a distinct
circardian rhythm in the occurrence of AF.33) A
shortening of the eﬀective refractory period of atrial
myocytes by vagal activity will result in AF in these
patients since shortening of the eﬀective refractory
period is considered to facilitate the development of
AF.34,35)
Recently, gene mutations of ionic channels have
been reported as the cause of familial AF.36–39) These
mutations are associated with abnormal function of
ionic channels and shortening of the refractory
period.38,39) AF develops in hyperthyroidism but
the cause has yet to be determined. We then,
conﬁrmed that the thyroid hormone (T3) induces
gene expression of Kv1.5: the potassium channel,
and reduces the gene expression of the L-type
calcium channel.40) This altered gene expression will
result in a shortening of the action potential duration
and this might be the mechanism of frequent AF
in hyperthyroidism.34,35) The ionic channels can be
altered by congenital abnormalities or by some other
disorders such as hyperthyroidism rendering the
atrium to develop AF easily. Of these underlying
diseases, recent clinical trials have been shown the
incidence of AF might be eﬃciently reduced by
some drugs and will be discussed later.
Prevalence of AF in the General Population
and Risk Factors
The epidemiology of AF has not been well known
until recently in this country.41,42) We have deter-
mined the prevalence of AF in the general popula-
tion.41) The subjects underwent an annual health
examination which was recommended for those
who were not under medication for either cardiac
or non-cardiac diseases, but 12.6% had been receiv-
ing medication for hypertension, diabetes etc. In
2003, 83,367 men (31.1% of the total male residents)
and 159,770 women (39.6% of the total female
residents) underwent the examination. ECG at the
time of the examination showed AF in 1.25% and the
prevalence of AF was higher in men than women
and in the elderly than in younger subjects (Figure 1).
These results were similar to those obtained in the
national survey in 300 districts conducted every 10
years in Japan.42) From these results, the number of
Japanese adults with AF might be estimated as more
than one million: 598,000 men and 457,000 women.
Risk factors leading to development of AF have
been elucidated in population-based studies.43–48) In
the Framingham study,43) a total of 2,090 men and
2,641 women free of a history of AF between the
ages of 55 and 94 years were followed for 38 years.
AF developed in 12.6% of men and 11.3% of women
and in the multivariable model, odds ratio (OR) of
developing AF for each decade of advancing age
was 2.1 for men and 2.2 for women. In addition,
diabetes mellitus (DM), hypertension, congestive
heart failure and valve disease were associated with
OR (men/women) of 1.4/1.6, 1.5/1.4, 4,5/5.9 and
Table 1 The prevalence of atrial ﬁbrillation (Ref. 20).
1 Hypertension: 7% (8.8%/5.0%)
2 Ischemic HD: 7% (7.3%/6.3%)
3 Dilated CM: 38% (36.3%/40.7%)
4 Hypertrophic CM: 10–20%
5 Valvular HD: 14–26%
6 Heart Failure: 20–35%
7 Hyperthyroidism: 1.7% (2.8%/1.4)
8 WPW syndrome: 15–30%
9 Sick sinus syndrome: 15–30%
10 Lone AF: 1–10%
HD: Heart Disease. CM: Cardiomyopathy. (Men/Women)
: Rose to 40–60% in Brady-tachy syndrome.
: Age dependent (<1%, 4–7% and 10% in <60, 70–79, >80
years of age)
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1.8/3.4, respectively. Myocardial infarction was a
risk factor in men (OR = 1.4). The incidence of AF
in the general population is considered to be 0.5 per
1000 person-years in those under 50 years and rose
to 9.7 per 1000-person years in those 70 years of
age.44) A similar age-dependent rise of the incidence
of AF was reproted by Psaty et al:45) 17.2 per 1000-
persons-years for those between 65–74 years and
42.7 per 1000 person-years for those between 75–84
years.
Risk factors for newly developed AF was ob-
served in this country and the incidence was found
to be lower than Western countries.48) The study was
conducted in 63,386 subjects aged 50 years,
without baseline AF, structural heart disease, or
heart failure, who completed the annual examination
during a 10-year follow-up period (1991–2002). AF
developed in 873 subjects (1.38%). The incidence
was 1.3 per 1000 person- years: 2.6 per 1000 person-
years for men and 0.9 per 1000 person- years for
women.
Age, male sex, body mass index, hypertension,
systolic and diastolic blood pressure, and diabetes
were signiﬁcant risk factors for the development of
AF (Figure 2). In multivariable logistic regression
analysis adjusted for these risk factors, electro-
cardiographic left ventricular hypertrophy (odds
ratio [OR], 1.43), ST-segment abnormality without
left ventricular hypertrophy (OR, 1.89), and the
presence of premature complexes during a 10-second
recording (OR, 2.89) were signiﬁcantly associated
with AF, whereas neither right nor left bundle branch
block was a risk factor.
Among risk factors in developing AF, some were
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Figure 1 Age distribution of atrial ﬁbrilla-
tion in Japanese people.
White: Total. Grey: Men. Black: Women (from
references 41 and 42).
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Figure 2 Development of atrial ﬁbrillation
and common risk factors with subsequent
stroke.
Common diseases such as hypertension (HTN),
diabetes mellitus (DM) or obesity are believed
to provide the arrhythmogenic substrate in the
atrium leading to development of atrial ﬁbrilla-
tion (AF). These risk factors including age or
sex(male) are the risks for stroke. Though not
shown, heart failure is another risk factor.
Structural and electrical remodeling are in-
volved for the development of AF.
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closely related to a metabolic abnormality: DM,
obesity and obstructive sleep apnea (OSA) as risk
factors for newly developed AF was reported in the
literature.
DM and/or metabolic syndrome is increasing in
developed countries and is a risk factor for the new
AF.45) In type II DM (n = 293,124), AF occurred in
14.9% DM patients vs. 10.3% in the non-matched
control without DM but with hypertension: OR =
2.13 (95% CI:2.10 to 2.16, p < 0.0001).50) The caus-
al link can be indirect via coronary artery disease,
hypertension or autonomic neuropathy but it can be
more direct. In the atrium of diabetic rats, over-
expression of oxidative stress was veriﬁed and most
likely it plays a role as a causative factor of AF.51)
Obesity is said to be reaching epidemic propor-
tions with nearly 65% of the population overweight
and nearly 31% obese in the USA52) and this has
been associated with new AF and cerebral stoke
events in AF patients.53–55) In the Framingham
study,50) 5,282 participants (mean age, 57  years;
2,898 women) without baseline AF were included.
During the mean follow-up of 13.7 years, 526
participants (234 women) developed AF. The age-
adjusted incidence rates for AF increased across the
3 BMI categories in men and were 9.7, 10.7, and
14.3 per 1000 person-years and in women 5.1, 8.6,
and 9.9 per 1000 person-years. The excess risk of AF
in obesity is considered to be mediated by left atrial
dilatation.53–55) Furthermore, the increased iunci-
dence of AF in obesity appeared partially mediated
by DM.54)
OSA is found in about 40% of obese individu-
als56–58) and patients with OSA were reported to be
signiﬁcantly frequent in the AF group than in the
general cardiology group (49% versus 32%, P =
0.0004): OR for the association between AF and
OSA was 2.19 (95% CI 1.40 to 3.42, P = 0.0006).56)
In OSA, autonomic, hemodynamic and hypoxe-
mic surges caused by apnea will activate some ionic
channels leading to greater focal discharges. Pulmo-
nary or systemic hemodynamics, lung physiology
restricted by morbid obesity or both can elevate
atrial pressures and trigger ectopy. Furthremore,
enhanced vagal reﬂexes activities in OSA would lead
to a shortening of the atrial refractory period and
might promote the conduction of focal discharges
from the pulmonary vein to the left atrium and
trigger AF.56–58) Elevated C-reactive protein (CRP),
a marker of risk of a cardiovascular event59) has been
associated with obesity, metabolic syndrome, se-
verity of OSA and AF.59–61) Obesity, OSA or both is
believed to promote atrial structural remodeling via
mechanical or inﬂammatory stress.
Prevention of AF
Whether proper management of underlying dis-
eases or disorders can prevent the occurrence of AF
or not is an important clinical issue (Figure 2). So far,
clinical trials in heart failure and hypertension have
shown that ACE-inhibitors and ARB have been
eﬀective in reducing the development of AF.
ACE inhibitors were suggested to reduce the
occurrence of arrhythmias and cardiac remodeling25)
and Trandolapril showed that it reduces the inci-
dence of AF after acute myocardial infarction with
left ventricular dysfunction. Of 1,749 patients ran-
domized to trandolapril or placebo, 1,577 had sinus
rhythm at baseline ECG.62) In the trandopril group,
2.8% developed AF while in the placebo group,
5.3% developed AF during the follow-up of 2–4
years (P < 0.05). Such reduction of the occurrence
of AF was conﬁrmed in the SOLVD study.63) Of
391 patients with sinus rhythm and depressed left
ventricular ejection fraction (<0:35) and asympto-
matic or mild symptoms of heart failure, 5.4% in
the enalapril group and 24% in the placebo group
developed AF during the follow-up period of 2:9
1:0 years (P < 0.0001).
In the Val-Heft study,64) new AF was observed in
287 (6.53%) among the 4,395 patients patients who
had sinus rhythm at baseline during 23 months of
follow-up. Multivariable analysis showed that the
brain natriuretic peptide (BNP) levels at baseline
above the median value, age over 70 years, and male
sex were risk factors for new AF. AF was reported in
113/2,205 (5.12%) allocated to the valsartan group
and in 174/2,190 (7.95%) to the placebo group
(P = .0002). Valsartan reduced the incidence of AF
by 37%. The occurrence of AF was independently
associated with a higher all-cause mortality and with
combined mortality/morbidity.
In the CHARM program,65) 7,601 patients with
symptomatic heart failure and reduced or preserved
left ventricular systolic function were randomly
administered candesartan or placebo and followed
for 37.7 months on average. Of these, 392 (6.15%)
developed AF during the follow-up, 177 (5.55%)
in the candesartan group and 215 (6.74%) in the
placebo group (OR 0.812, 95% CI 0.662–0.998,
P = .048).
The recurrence rate of AF after cardioversion of
persistent AF was reduced by ACE-inhibitor or
ARB.66,67) The beneﬁcial eﬀect of ACE-inhibitors or
ARBs was seen in meta-analysis.68,69) A rise in the
atrial pressure or an increased atrial size is believed
to be important in developing AF but, it was diﬃcult
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to predict the occurrence of AF from clinical or
hemodynamic variables in heart failure.70) Decreased
mitral ﬂow velocity might be observed prior to
AF.70)
Hypertension is an important risk factor for the
occurrence of AF and can be regarded as the major
source of AF in the community. In the STOP-
Hypertension 2 trial,71) 6,614 elderly patients were
included and the incidence of the cardiovascular
events were assessed in 3 treatment regimens;
conventional antihypertensive drugs (atenolol, me-
toprolol, pindolol or hydrochlorothiazide plus ami-
loride) and newer drugs at that time (enalapril,
lisinopril, ﬂedipine, or isradipine). New AF devel-
oped in 16.5/1,000 person-years but the incidence
was not aﬀected by drugs. The incidence was
relatively high compared to subsequent studies72–74)
and this might be due to the patients being aged 70–
84 years and some had severe hypertension: blood
pressure 180mmHg systolic, or 105mmHg dia-
stolic. More importantly, the attained blood pressure
was high, around 159mmHg (systolic).
The Nordic Diltiazem (NORDIL) study72) was
another prospective, randomised, open, blinded
endpoint study and 10,881 patients, aged 50–74
years were treated in two treatment regimens:
diltiazem with diuretics, beta-blockers, or both.
Blood pressure fell similary in both groups from
174 18/105 5 to 152 16/88 8mmHg in
the diltiazem group and from 173 18/106 5 to
149 17/87 8mmHg in the other group and new
AF occurred in 4.2 vs. 5.1 per 1000-person years
respectively. The two studies showed no diﬀerence
in the incidence of AF among drugs used.
However, in the LIFE study,73) the patients with
hypertension associated with ECG-documented left
ventricular hypertrophy were followed for 4:8 1:0
years and losartan or atenolol was administered.
New-onset AF occurred in 150 patients randomly
administered with losartan vs. 221 with atenolol (6.8
vs. 10.1 per 1,000 person-years; the relative risk was
0.67, 95% conﬁdence interval [CI] 0.55 to 0.83,
p < 0.001) despite similar blood pressure reduction.
Finally, the most recent study of VALUE74) inves-
tigated the outcomes in 15,245 high-risk hyper-
tensive subjects who were treated with valsartan-
or amlodipine-based regimens. For the ﬁrst time,
the attained systolic blood pressure fell below 140
mmHg on average in this study. AF developed newly
in 4.8/1,000 person-years in the valsaratan group
and lower compared to the calcium channel blocker
amlodipine group: 5.8/1,000 person-years. Thus,
recent studies showed ARB reduces the incidence of
AF in hypertensive therapy.
The studies and results of hypotensive therapy
were summarized in Figure 3. It is of note that the
incidence of AF was high in the STOP-Hyper-
tension-2 study but low in the VALUE study.71,74)
One reason can be the ﬁnding that attained blood
pressure was high:160mmHg in the former but in the
VALUE study, the attained blood pressure was for
the ﬁrst time below 140mmHg. Another reason
can be that the age of the patients: in the STOP
Hypetension-2 was high (>80 years) compared to
those of VALUE. However, the CAPP study in-
cluded younger aged patients: 20–66 years75) and the
attained blood pressure and the incidence of AF were
similar to STOP-Hypertension-2. Therefore, in hy-
potensive therapy, it seems very important to treat
hypertension strictly and also to choose either an
ACE-inhibitor or ARB. Such therapy can be a prom-
ising upstream therapy of AF.76)
In summary, AF is a common arrrhythmia and
develops in association with common diseases
(Figure 2). Once AF occurs, AF is associated with
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Figure 3 Incidence of AF vs achieved
blood pressure in hypotensive therapy.
The incidence of AF against the achieved blood
pressure (systolic) in 5 clinical trials of hypo-
tensive therapy were plotted. Number means the
reference number (from references 71–75).
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increased morbidity and mortality and the proper
therapy of AF is mandatory: anticoagulant therapy to
prevent stroke and antiarrhythmic agents or catheter
ablation to prevent recurrence of AF. The risk factors
to develop AF are also risk factors for stroke to occur
and the proper treatments are warranted.7–9,12,13,43)
However it is to be stressed that AF might be
reduced by the proper use of drugs which inhibit
RAS and the strict control of the underlying diseases
as proved in heart failure and hypertension.
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